Home NDC 0002-8233-01 NDC 0002-8233-01 - Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 KwikPen This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
Product NDC 0002-8233
Requested NDC 0002-8233-01
Package NDCs from labels 0002-8233-01, 0002-8233-05
Manufacturer Eli Lilly and Company
Effective date 2024-08-06
Current FDA listing Not matched in FDA.report NDC product tables DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 0002-8233-01 Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 KwikPen 3 mL in 1 SYRINGE INJECTION, SUSPENSION 3 11 0002-8233-05 Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 KwikPen 5 in 1 CARTON INJECTION, SUSPENSION 5 11
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 0002-8233 INSULIN LISPRO PROTAMINE AND INSULIN LISPRO INJECTABLE SUSPENSION MIX75/25 KWIKPEN (INSULIN LISPRO) INJECTION, SUSPENSION [ELI LILLY AND COMPANY] 11 Current NDC, Legacy NDC, 2 package rows 20240809_e49f701d-c19f-4cb2-b63f-01a917b33abc.zip
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 114 of 232 · 4,639 matching rows.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.